Clinical Applications

Acute Respiratory Distress Syndrome

Respirogen OMB technology will provide oxygen independent from damaged lungs. Acute respiratory distress syndrome (ARDS) is an acute severe lung disease commonly encountered in intensive care units (ICU). It can be caused by several triggers, including pneumonia or trauma. It is characterized by widespread injury of the alveolar–capillary membrane, resulting in protein rich noncardiogenic pulmonary edema (fluid accumulation in the lungs) and acute respiratory failure (ARF). ARDS results in severe  hypoxaemia, which is refractory to oxygen treatment and requires assisted ventilation.

Oxygenation Prior to Intubation


Respirogen OMB technology will provide extended O2 saturation time by intraperitoneal injection of OMB, to extend safe apnea time in intubation. Intubation procedures require a break in mechanical ventilation, which leads to severe hypoxia in 26%, hemodynamic collapse in 25%, and cardiac arrest in 2% of ICU intubations. Patients today undergo pre-oxygenation to increase oxygen reserves in the body which can increase safe apnea time from 1 minute to 8 minutes in healthy adults. Pediatrics and critically ill patients can desaturate much faster, as quickly as 23 seconds.

Wound Healing


Diabetic Foot Ulcers (DFU) form in 25% of diabetics during their life. Cost to private and public (Medicare) insurers was $9-13 billion in 2012 (in addition to costs associated with diabetes itself). Many DFUs occur secondary to peripheral artery disease (PAD), which results in a state of chronic hypoxia in the tissue due to inadequate vascular perfusion. Treatment consists of debridement, moist dressings, and offloading areas of high pressure or friction as well as hyperbaric oxygen therapy (HBOT) or Continuous Diffusion of Oxygen (CDO). Local oxygen delivery by OMB may promote early healing and tissue oxygenation.

Research Opportunities


Multiple basic research opportunities have been identified for development of clinical OMB therapies: ARDS smoke inhalation model; Hypoxia large animal model for battlefield injury and transport; IRDS (NICU) surfactant  therapy for infant respiratory distress; Cancer, oral ingestion for reduction of tumor hypoxia; Consumer products: OTC Cosmetic applications.